[Transplantation of allogeneic mesenchymal stem cells from the bone marrow increases duration of remission and reduces the risk of ulcerative colitis relapse].
The first results of allogeneic mesenchymal stem cells from the bone marrow transplantation to patients with ulcerative colitis demonstrated improved clinical course. We found an increasing in the duration of remission in patients with chronic recurrent and continuous recurrent course of ulcerative colitis. Also it was noted reducing the risk of relapse, and reducing the frequency of hospital admissions compared with medication therapy with only 5 aminosalicylic acid and glucocorticosteroid.
Lazebnik
L B
LB
Kniazev
O V
OV
Parfenov
A I
AI
Ruchkina
I N
IN
Rogozina
V A
VA
Konopliannikov
A G
AG
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001854:Bone Marrow Cells; D003093:Colitis, Ulcerative / Q000628:therapy*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage*; D045164:Mesenchymal Stem Cell Transplantation; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D014184:Transplantation, Homologous
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D019804:Mesalamine